Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening

被引:51
作者
Goetz, Christopher G. [1 ]
Fan, Wenqing [1 ]
Leurgans, Sue [1 ]
机构
[1] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA
关键词
Parkinson's disease; hallucinations; antipsychotic medication;
D O I
10.1002/mds.22132
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To test if antipsychotic medication treatment of Parkinson's disease (PD) patients with mild hallucinations and retained insight delays deterioration to delusions or hallucinations without insight. We identified subjects at the time they developed their first hallucination, based on documented progression in their UPDRS thought disorder (TD) score from <2 to 2 ("benign" hallucinations with insight retained). We registered TD scores at follow-up visits and their hallucination treatment: antipsychotic medication, PD medication reduction. or observation. The primary outcome measure was the time from the first TD = 2 until the TD score worsened to 3 (hallucinations with loss of insight or 4 (delusions, psychosis). The effect of antipsychotic medication treatment on transition hazard rate was modeled by proportional hazards regression (Cox model) with antipsychotic medication use as a time-dependent covariate. Of 64 patients, 31 received antipsychotic medication during the study (mean group follow-up 31 months). Of the 38 Subjects who reached endpoint. eight subjects had been treated will, antipsychotic medication compared to 30/33 in those not treated with antipsycholic medication. Antipsychotic medication treatment reduced the risk of deterioration [hazard ratio = 0.156, CI = (0.067-0.363) P < 0.0001] compared to treatment without antipsychotic medications. The median time from the introduction of antipsychotic medication to the conversion from TD = 2 to TD > 2 was 39 months in Subjects on antipsychotic medication compared to 12 months in patients treated otherwise. Until randomized treatment trials provide definitive information. early antipsychotic medication treatment for mild hallucinations Should be considered with the combined coal of improving Current hallucinations and reducing risks of later deterioration. (c) 2008 Movement Disorder Society.
引用
收藏
页码:1541 / 1545
页数:5
相关论文
共 17 条
[1]   Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study [J].
Aarsland, D ;
Larsen, JP ;
Tandberg, E ;
Laake, K .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (08) :938-942
[2]   Risk factors for somnolence, edema, and hallucinations in early Parkinson disease [J].
Biglan, Kevin M. ;
Holloway, Robert G., Jr. ;
McDermott, Michael P. ;
Richard, Irene H. .
NEUROLOGY, 2007, 69 (02) :187-195
[3]   Clozapine and risperidone treatment of psychosis in Parkinson's disease [J].
Ellis, T ;
Cudkowicz, ME ;
Sexton, PM ;
Growdon, JH .
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2000, 12 (03) :364-369
[4]  
Fahn S., RECENT DEV PARKINSON, V2, P153, DOI DOI 10.1002/ANA.410220556
[5]   Hallucinations in Parkinson's disease -: Prevalence, phenomenology and risk factors [J].
Fénelon, G ;
Mahieux, F ;
Huon, R ;
Ziégler, M .
BRAIN, 2000, 123 :733-745
[6]   Scales to assess psychosis in Parkinson's disease:: Critique and recommendations [J].
Fernandez, Hubert H. ;
Aarsland, Dag ;
Fenelon, Gilles ;
Friedman, Joseph H. ;
Marsh, Laura ;
Troster, Alexander I. ;
Poewe, Werner ;
Rascol, Olivier ;
Sampalo, Cristina ;
Stebbins, Glenn T. ;
Goetz, Christopher G. .
MOVEMENT DISORDERS, 2008, 23 (04) :484-500
[7]  
Friedman J, 1999, NEW ENGL J MED, V340, P757
[8]  
Goetz C G, 1999, Adv Neurol, V80, P419
[9]   The malignant course of "benign hallucinations" in Parkinson disease [J].
Goetz, CG ;
Fan, WQ ;
Leurgans, S ;
Bernard, B ;
Stebbins, GT .
ARCHIVES OF NEUROLOGY, 2006, 63 (05) :713-716
[10]   RISK-FACTORS FOR NURSING-HOME PLACEMENT IN ADVANCED PARKINSONS-DISEASE [J].
GOETZ, CG ;
STEBBINS, GT .
NEUROLOGY, 1993, 43 (11) :2227-2229